Brief: KOMZIFTI Gets FDA Approval For Adults With Relapsed Or Refractory NPM1-Mutated AML
13/11/2025 18:43
Nov 13 (Reuters) - Kura Oncology KURA.O: KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FDA APPROVAL OF KOMZIFTI™ (ZIFTOMENIB), THE FIRST AND ONLY ONCE-DAILY TARGETED THERAPY FOR ADULTS WITH RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA Source text: ID:nGNX4LHHQf Further company coverage: KURA.O ((Reuters.Briefs@thomsonreuters.com;))